Brief: In8bio Announces Positive INB-200 Phase 1 Data Update In Glioblastoma At The 2023 ASCO Annual Meeting

IN8bio

05/06/2023 16:26

June 5 (Reuters) - IN8BIO, Inc.  INAB.O :
    * IN8BIO ANNOUNCES POSITIVE INB-200 PHASE 1 DATA UPDATE IN
GLIOBLASTOMA AT THE 2023 ASCO ANNUAL MEETING
    * IN8BIO, INC. - ON TRACK TO COMPLETE INB-200 PHASE 1 STUDY
ENROLLMENT IN 2023 WITH UPDATED DATA EXPECTED LATER THIS YEAR
    * IN8BIO- INB-200 CONTINUES TO EXHIBIT A MANAGEABLE SAFETY
PROFILE
WITH MINIMAL TOXICITIES AND REPEAT DOSING DEMONSTRATED NO CHANGE
IN TOXICITY PROFILE
    * IN8BIO, INC. - NO TREATMENT-RELATED DEATHS HAVE BEEN
REPORTED IN
ANY COHORT
    * IN8BIO, INC. - SIX DEATHS WERE OBSERVED, THREE DUE TO
PROGRESSION OF DISEASE AND THREE UNRELATED TO EITHER TREATMENT
OR PROGRESSION

Source text for Eikon:  ID:nGNX8C5n5R 
Further company coverage:  INAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))